Santarus Submits Ind for Phase III Clinical Testing of Rifamycin SV MMX in Travelers’ Diarrhea

Santarus, Inc. , a specialty biopharmaceutical company, today announced that it has submitted an Investigational New Drug application to the U.S. Food and Drug Administration requesting approval to begin a Phase III clinical program evaluating rifamycin SV MMX in patients with travelers’ diarrhea.

Popularity: 1% [?]

Share this Post:
Digg Google Bookmarks reddit Mixx StumbleUpon Technorati Yahoo! Buzz DesignFloat Delicious BlinkList Furl

No Responses to “Santarus Submits Ind for Phase III Clinical Testing of Rifamycin SV MMX in Travelers’ Diarrhea”

Leave a Reply:

Name (required):
Mail (will not be published) (required):
Website:
Comment (required):
XHTML: You can use these tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

Get Adobe Flash playerPlugin by wpburn.com wordpress themes